Supplementary Fig. 4 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)

Supplementary Fig. 4.(A) Average number of mitotic cells per treatment group in 10 high power fields assessed on phospho-histone H3 (pHH3) immunostaining and (B) percentage of proliferative cells per treatment group per 5 high-power fields assessed on Ki-67 immunostaining.